Investment treaty disputes in the life sciences industry
In its global scale and economic impact, the life sciences industry presents unique considerations for investment treaty arbitrations. Recently, the COVID-19...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s Life Sciences consultants have authored a variety of articles on the effects of the Covid-19 pandemic on life sciences companies, covering issues including the impact on clinical research, physician practices, and vaccine pricing, procurement, and supply. You can read a selection of our thinking below.
In its global scale and economic impact, the life sciences industry presents unique considerations for investment treaty arbitrations. Recently, the COVID-19...
CRA surveyed 36 MedTech leaders to understand their strategic priorities and the impact of COVID-19 on their business. Survey respondents work in leadership...
The COVID-19 pandemic has had a significant impact – both positive and negative – on MedTech customers as well as the MedTech industry itself. Almost all...
The COVID-19 pandemic has had a significant impact – both positive and negative – on MedTech customers as well as the MedTech industry itself. Similar to how...